Monday, March 1, 2010 (Last Updated: 03/02/2010)
MONDAY, March 1 (HealthDay News) -- It is questionable whether elderly patients with invasive bladder cancer benefit from radical cystectomy, as the period of overall survival is heavily dependent on tumor stage and age, according to a study published in the February issue of Urology, while a second study found that comorbidities play a significant role in survival odds for invasive bladder cancer patients.
Clemens Wehrberger and colleagues at the Donauspital Langobardenstrasse in Vienna, Austria, analyzed data on 71 patients (mean age, 86 years) who underwent transurethral resection to treat invasive bladder cancer, and found that the mean overall survival was 34 months for those with pT1 tumors and 14 months for those with tumors at or above stage pT2.
Lars Lund, M.D., of Viborg Hospital in Denmark, and colleagues analyzed data on 3,997 invasive bladder cancer patients, of whom 1,715 (43 percent) had comorbid conditions, and found that five-year mortality rates were significantly higher for these patients compared to those with no comorbidities.
"Bladder cancer provides a difficult dilemma to physicians: an elderly population with significant comorbidities, combined with an unforgiving disease if left untreated," write the authors of a related editorial. "Consequently, the urologist must weigh the comorbidities and life expectancy of each patient with the likelihood of benefit of radical cystectomy, a procedure that can be fraught with morbidity and mortality."
Copyright © 2010 HealthDay. All rights reserved.